Hims & Hers vs Fridays (2026): prices, structure, verdict

On tirzepatide, only Fridays has a rankable figure: $359 a month all-in; Hims & Hers↗ routes tirzepatide through brand channels without a single compounded cash price — its cost depends on coverage or the manufacturer programs (Zepbound vials $299–$449; Wegovy $349).

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, only Fridays has a rankable figure: $175 a month all-in; Hims & Hers routes semaglutide through brand channels without a single compounded cash price — its cost depends on coverage or the manufacturer programs (Zepbound vials $299–$449; Wegovy $349).

§ Side by side

§ Each record, read aloud

The two records, condensed

Hims & Hers: the record, condensed

On tirzepatide, Hims & Hers is a brand channel rather than a priced product: it prescribes the FDA-approved medication, and what you pay depends on coverage or the manufacturer cash programs (Zepbound (LillyDirect↗) at $299–$449).

Hims & Hers routes semaglutide through brand product — no single compounded cash figure exists to rank. The reference prices live one layer down: Wegovy (NovoCare↗), $199–$349 a month cash, or whatever your insurance turns those numbers into.

Operationally at Hims & Hers: shipping included; commitment plan recurs; cancellation plan recurs until cancelled; pharmacy named (brand fulfillment; compounded program closed to new patients); states: 50 states; evidence no public price, captured 2026-08-05. The full record with source and archive links: the Hims & Hers page · visit Hims & Hers ↗

Fridays: the record, condensed

Start with the load-bearing figure: $359 a month, all-in, is what Fridays charges for tirzepatide at the 10 mg basis. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $359 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #13 of 17 in the verified tirzepatide index — $144/month above the floor (NexLife↗, $215) — and sits $90 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $4,308.

Start with the load-bearing figure: $175 a month, all-in, is what Fridays charges for semaglutide at the 2.4 mg basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #7 of 20 verified programs, with the floor $42/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $174 a month. A year at this figure: $2,100 monthly-billed.

Operationally at Fridays: shipping included; commitment annual plan for lowest rate; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Fridays page · visit Fridays ↗

§ Structure vs structure

Everything besides the price

Coverage: Hims & Hers publishes “50 states”; Fridays publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: Hims & Hers names its network (brand fulfillment; compounded program closed to new patients); Fridays does not, which shifts the burden of verification onto your intake questions.

Exit terms: Hims & Hers — plan recurs; plan recurs until cancelled. Fridays — annual plan for lowest rate; not published.

Evidence: Hims & Hers no public price (captured 2026-08-05); Fridays third-party reported (2026-08-05).

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

§ If you move

Switching between Hims & Hers and Fridays

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Hims & Hers: plan recurs until cancelled; Fridays: not published) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings